Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 5
1989 11
1990 39
1991 43
1992 38
1993 66
1994 86
1995 95
1996 90
1997 72
1998 103
1999 77
2000 63
2001 48
2002 45
2003 53
2004 42
2005 56
2006 50
2007 48
2008 45
2009 47
2010 58
2011 49
2012 66
2013 87
2014 67
2015 51
2016 70
2017 53
2018 48
2019 49
2020 39
2021 37
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,767 results
Results by year
Filters applied: . Clear all
Page 1
Granisetron.
Nodoushani M. Nodoushani M. Conn Med. 1995 Apr;59(4):209-11. Conn Med. 1995. PMID: 7606907 Review. No abstract available.
Transdermal granisetron.
Duggan ST, Curran MP. Duggan ST, et al. Drugs. 2009;69(18):2597-605. doi: 10.2165/11202780-000000000-00000. Drugs. 2009. PMID: 19943709 Review.
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomitin
The safety of early pregnancy exposure to granisetron.
Shapira M, Avrahami I, Mazaki-Tovi S, Shai D, Zemet R, Barzilay E. Shapira M, et al. Eur J Obstet Gynecol Reprod Biol. 2020 Feb;245:35-38. doi: 10.1016/j.ejogrb.2019.11.033. Epub 2019 Nov 29. Eur J Obstet Gynecol Reprod Biol. 2020. PMID: 31841778
RESULTS: 100 Granisetron exposed pregnancies were compared with 108 granisetron unexposed pregnancies. Exposure to granisetron occurred in the first trimester in 88 patients (94 fetuses). ...
RESULTS: 100 Granisetron exposed pregnancies were compared with 108 granisetron unexposed pregnancies. Exposure to graniset
Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED. Deeks ED. Drugs. 2016 Dec;76(18):1779-1786. doi: 10.1007/s40265-016-0664-2. Drugs. 2016. PMID: 27915445 Review.
Granisetron ER is administered as a single subcutaneous injection and uses an erosion-controlled drug-delivery system to allow prolonged granisetron release. ...Granisetron ER injection is generally well tolerated, with an adverse event profile similar to tha
Granisetron ER is administered as a single subcutaneous injection and uses an erosion-controlled drug-delivery system to allow prolon
Development of Nasal Mucoadhesive Microspheres of Granisetron: A Potential Drug.
Pandey J, Shankar R, Kumar M, Shukla K, Kumari B. Pandey J, et al. Drug Res (Stuttg). 2020 Aug;70(8):367. doi: 10.1055/a-1193-4781. Epub 2020 Jun 19. Drug Res (Stuttg). 2020. PMID: 32559774
BACKGROUND: Granisetron is a serotonin 5-HT(3) receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. ...CONCLUSION: After all the evaluation parameters and result obtained it can be said that these results confirmed …
BACKGROUND: Granisetron is a serotonin 5-HT(3) receptor antagonist used as an antiemetic to treat nausea and vomiting following chemo …
Granisetron protects polymicrobial sepsis-induced acute lung injury in mice.
Wang J, Gong S, Wang F, Niu M, Wei G, He Z, Gu T, Jiang Y, Liu A, Chen P. Wang J, et al. Biochem Biophys Res Commun. 2019 Jan 22;508(4):1004-1010. doi: 10.1016/j.bbrc.2018.12.031. Epub 2018 Dec 11. Biochem Biophys Res Commun. 2019. PMID: 30551881 Free article.
Here we aimed to identify the novel effect of granisetron on sepsis-induced acute lung injury (ALI). Our results showed that mice treated with granisetron displayed less severe lung damage than controls. Granisetron administration reduced pulmonary neutrophil …
Here we aimed to identify the novel effect of granisetron on sepsis-induced acute lung injury (ALI). Our results showed that mice tre …
Granisetron.
Ignoffo RJ. Ignoffo RJ. Cancer Pract. 1994 May-Jun;2(3):229-31. Cancer Pract. 1994. PMID: 8055027
Granisetron is the second agent in the 5-HT3 receptor antagonist class to be approved for the prophylaxis of acute emesis caused by cancer chemotherapy. ...Additional studies will be needed to determine the role of granisetron in the current management of chemothera
Granisetron is the second agent in the 5-HT3 receptor antagonist class to be approved for the prophylaxis of acute emesis caused by c
Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M. Minami M. Cancer Chemother Pharmacol. 2003 Aug;52(2):89-98. doi: 10.1007/s00280-003-0652-6. Epub 2003 May 29. Cancer Chemother Pharmacol. 2003. PMID: 12783208 Review.
The aim of this article is to examine the hypothesis that there is a dose-response effect of granisetron for preventing chemotherapy-induced nausea and vomiting in cancer patients. ...CONCLUSIONS: Those patients experiencing inadequate control of nausea and vomiting follow …
The aim of this article is to examine the hypothesis that there is a dose-response effect of granisetron for preventing chemotherapy- …
Granisetron: the second serotonin-receptor antagonist.
Adams VR, Valley AW. Adams VR, et al. Ann Pharmacother. 1995 Dec;29(12):1240-51. doi: 10.1177/106002809502901211. Ann Pharmacother. 1995. PMID: 8672830 Review.
DATA SOURCES: MEDLINE (1966-1995) and CANCERLIT (1991-1995) searches of English-language literature using the terms "granisetron" and "granisetron (rn)" were performed. STUDY SELECTION AND DATA EXTRACTION: All articles were considered for possible inclusion in this …
DATA SOURCES: MEDLINE (1966-1995) and CANCERLIT (1991-1995) searches of English-language literature using the terms "granisetron" and …
Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?
Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2017 Jul;18(10):1019-1026. doi: 10.1080/14656566.2017.1342809. Epub 2017 Jun 19. Expert Opin Pharmacother. 2017. PMID: 28612633 Review.
Area covered: In an attempt to maintain plasma levels of granisetron during the delayed phase of CINV, longer-acting preparations of granisetron have been manufactured. ...At present, it seems likely that there will be ongoing roles for intravenous and subcutaneous …
Area covered: In an attempt to maintain plasma levels of granisetron during the delayed phase of CINV, longer-acting preparations of …
1,767 results